Research pipeline
We combine the pioneering science of our collaborators with the recognised expertise of our core partners. Together, we are advancing a pipeline of potential first-in-class or best-in-class, child-focused therapeutic assets to address some of the most challenging indications in paediatric cancer.
CF-012
A potential first-in-class, ETV6 inhibitor for the treatment of Ewing sarcoma
In collaboration with:
University of Virginia
Dana-Farber Cancer Institute
Mass General Brigham
CF-033
A potential first-in-class allogeneic, PRAME-targeting iNKT cell therapy to treat advanced cancers in young patients
In collaboration with:
MiNK Therapeutics
University of Southampton
Work with us
Whether you’re a researcher with a therapeutic opportunity, a potential partner or an impact investor, we want to hear from you.
Research collaborations
Are you a research team, with a promising validated target in paediatric cancer? Our next deadline for expressions of interest is 13 March 2026.
Learn more
Partnering & investment opportunities
Are you an investor, or interested in partnering opportunities?
Explore partnering
News and events
We are creating a consortium united in the unwavering belief that we can challenge conventional approaches and accelerate translation of promising ideas into new therapies for children and young people affected by cancer.
Stay up to date on our latest news, events and research.
From Chemo to CAR-T: A mum’s call for Child-First Drug Design
Courtney Addison on her son Cayden's cancer journey and the need for more targeted paediatric cancer treatments in an interview with C-Further.
Annual review 2024-2025
C-Further reports on our progress and activities since launch in our annual review of 2024-2025
C-Further announces major partnership with GOSH Charity to drive innovation in childhood cancer treatment
GOSH Charity joins Cancer Research Horizons and LifeArc as a core partner of C-Further.
Voices for paediatric progress: Iris Valtingojer
Iris Valtingojer, PhD, shares her vision for transforming childhood cancer R&D through innovation, equity, and collaboration.